host, said method comprising:

administering to said host an effective amount of a pharmaceutical composition comprising an active agent that modulates the sulfation activity of a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3) and KSGal6ST and homologues thereof.

19. (Amended) The method according to Claim 18, wherein said active agent inhibits the sulfation activity of said glycosyl sulfotransferase.

23. (Amended) A method of modulating a symptom in a mammalian host of a disease condition associated with a selectin mediated binding event, said method comprising:

administering to said host a pharmaceutical composition comprising an effective amount of an active agent that modulates the sulfation activity of a sulfotransferase selected from the group consisting of glycosyl sulfotransferase-3 (GST-3) and KSGal6ST and homologues thereof.

-- 30. (New) The method of claim 16, wherein the GST-3 is encoded by a nucleic acid having a sequence that is at least 75% identical to SEQ ID NO:2.

31. (New) The method of claim 16, wherein the selectin ligand is selected from the group consisting of an L-selectin ligand, a P-selectin ligand, and an E-selectin ligand.

32. (New) The method of claim 16, wherein the selectin is an L-selectin, and the selectin ligand is an L-selectin ligand.

33. (New) The method of claim 19, wherein the agent is an antibody specific for GST-3.

34. (New) The method of claim 19, wherein the agent is a small molecule.

35. (New) The method of claim 18, wherein the GST-3 is encoded by a nucleic acid having a sequence that is at least 75% identical to SEQ ID NO:2.

36. (New) The method of claim 23, wherein said disease condition is selected from the group